Results 231 to 240 of about 136,022 (256)

Interfacial Bioengineering of Dynamic Networks Hybrid Hydrogel for Programmed Intervention in Oral Precancerous Epithelial States

Advanced Healthcare Materials, EarlyView.
This study develops a dual‐bioinspired hydrogel, MSA@PGel (macrophage membrane‐coated and salvianolic acid B/5‐aminolevulinic acid co‐loaded liposomes embedded in a polydopamine‐based gel), that integrates macrophage membrane‐mediated active targeting and mussel‐inspired wet adhesion for programmed intervention in oral precancerous lesions.
Xiaoxian Zhao, Ao Zheng, Zhengyan Zhao, Qilin Li, Tianhao Wan, Tanjun Deng, Ying Zhang, Lingyan Cao, Lan Wu   +8 more
wiley   +1 more source

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48. [PDF]

J Immunother Cancer
Xiao J, Liu J, Zhang C, Liu Z, Nie Z, Yi Z, Gao X, Liang H, Huang J, Cai Z, Yan L, Wu B, Liu Z, Chen J, Zu X, Hu J.   +15 more
europepmc   +1 more source

The Impact of Conjugation Mode and Site on Tubulysin Antibody-Drug-Conjugate Efficacy and Stability. [PDF]

ChemistryOpen
Yamazoe S, Cheng Q, Kotapati S, Rangan VS, Sung MC, Deshpande M, Jashnani A, Qiang C, Smith MJ, Pan C, Dollinger G, Rajpal A, Strop P, Rao C.   +13 more
europepmc   +1 more source

Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. [PDF]

J Transl Med
Blomquist MR, Noviello TMR, Sereduk C, Grief D, Caruso FP, Sharma R, Garcia-Mansfield K, Pirrotte P, Kloss J, D'Angelo F, Marin BM, Porath K, Jain S, Rabichow B, Ensign SPF, Iavarone A, Paladino A, Sarkaria JN, Loftus JC, Ceccarelli M, Tran NL.   +20 more
europepmc   +1 more source

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors. [PDF]

Cancer Res Commun
Rohrberg KS, Lopez JS, Milhem MM, Blank CU, Reijers I, Thistlethwaite F, Plummer R, Piha-Paul SA, Jänne PA, Shum E, Shaw HM, Debruyne PR, Lao C, Baurain JF, Choe JH, Gort E, Zhao Y, Jerusalem G, Schöffski P, Chen AW, Cohen EA, Mankowski WC, Roshkovan L, Katz SI, Kontos D, Brady LK, Qutaish M, Castro PG, Pencheva N, Bajaj G, Fu Y, Windfeld K, Reiter P, Jure-Kunkel M, Higgs BW, Amiri KI, Ahmadi T, Forssmann U, Ramalingam SS, Vergote I.   +39 more
europepmc   +1 more source

Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer. [PDF]

Genome Res
Guardia GDA, Dos Anjos CH, Rangel-Pozzo A, Dos Santos FF, Birbrair A, Asprino PF, Camargo AA, Galante PAF.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Click Nucleophilic Conjugate Additions to Activated Alkynes: Exploring Thiol-yne, Amino-yne, and Hydroxyl-yne Reactions from (Bio)Organic to Polymer Chemistry

Chemical Reviews, 2021
Joshua C Worch, Matthew J Price, Andrew Dove   +2 more
exaly  

Hodgkin lymphoma: A review and update on recent progress

Ca-A Cancer Journal for Clinicians, 2018
Satish P Shanbhag, Richard F Ambinder
exaly  

Recent Advances in Metal-Catalyzed Asymmetric 1,4-Conjugate Addition (ACA) of Nonorganometallic Nucleophiles

Chemical Reviews, 2018
Ke Zheng, Xiaohua Liu, Xiaoming Feng
exaly  

Conjugate Additions of Nitroalkanes to Electron-Poor Alkenes:  Recent Results

Chemical Reviews, 2005
Roberto Ballini, Giovanna Bosica, Dennis Fiorini   +2 more
exaly